Učitavanje...
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonst...
Spremljeno u:
| Izdano u: | Clin Med Insights Oncol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4798019/ https://ncbi.nlm.nih.gov/pubmed/27013902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.Ss34534 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|